Trial Profile

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasiglucagon (Primary)
Indications Hypoglycaemia
Focus Proof of concept; Therapeutic Use

Most Recent Events

23 Mar 2022 Primary endpoint has been met. (Nadir plasma glucose concentration within two hundred forty minutes after MMT for 80 ug and 200 ug), as per Results published in the Diabetes Care
23 Mar 2022 Results published in the Diabetes Care
25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com